Washington, D.C., partner and co-chair of the IP Group Bob Stoll was quoted in a recent article published in Bloomberg BNA’s  Life Sciences Law & Industry Report titled, “Court Rules Genetic's DNA Analysis Method Patent Invalid.” The article discusses the court’s decision that the patent in question “seeks to cover a law of nature and fails to do significantly more than describe a natural phenomenon.”

The invention covers unpatentable subject matter according to the two-step framework outlined in Mayo Collaborative Servs. v. Prometheus Labs Inc by the U.S. Supreme Court. Bob commented on the ruling, saying that this case is “further evidence that the Mayo ruling is being too broadly applied in a way that hurts the medical diagnostic and personalized medicine industries.”

Read: “Court Rules Genetic's DNA Analysis Method Patent Invalid”
Source: Bloomberg BNA